Role of 5‐hydroxytryptaminergic and adrenergic mechanism in antagonism of reserpine‐induced hypothermia in mice

@article{Slater1979RoleO5,
  title={Role of 5‐hydroxytryptaminergic and adrenergic mechanism in antagonism of reserpine‐induced hypothermia in mice},
  author={Irwin H. Slater and Robert C. Rathbun and Richard W. Kattau},
  journal={Journal of Pharmacy and Pharmacology},
  year={1979},
  volume={31}
}
Antagonism of reserpine-induced hypothermia, a standard test for antidepressant agents (Askew 1963 ; van Riezen & Delver 1971), could reflect inhibition of reuptake of either 5-hydroxytryptamine (5-HT) or noradrenaline since both amines influence temperature regulation. Most tricyclic antidepressants inhibit reuptake of both amines but selective agents have become available. Fluoxetine is a specific inhibitor of 5-HT uptake and its chemical congener, nisoxetine has a greater effect on… 
The influences of reserpine and imipramine on the 5-HT2 receptor binding site and its coupled second messenger in rat cerebral cortex.
TLDR
The dynamic changes and adaptability of the receptor system, followed by changes in PI turnover are demonstrated, providing an explanation at the molecular level for the bases of depression and the role of antidepressant drugs effects on those pathological linking elements.
Biochemical and pharmacological tests for the prediction of ability of monoamine uptake blockers to inhibit the uptake of noradrenaline in‐vivo: the effects of desipramine, maprotiline, femoxetine and citalopram *
TLDR
It is concluded that functional in‐vivo tests for NA uptake inhibitors are more sensitive than the H 77/77 biochemical test; moreover, femoxetine, which in in-vitro studies is less selective than citalopram, may inhibit the uptake of NA in‐ vivo.
Development of antidepressant drugs. Fluoxetine (Prozac) and other selective serotonin uptake inhibitors.
TLDR
Some of the background which attracted the attention, and some studies on the chemical series of phenoxyphenylpropylamines and the enantiomers of fluoxetine and its major metabolite norfluoxetines as inhibitors of 5-HT and NE uptake in vitro are presented.
Ro 11-2465 (cyan-imipramine), citalopram and their N-desmethyl metabolites: Effects on the uptake of 5-hydroxytryptamine and noradrenaline in vivo and related pharmacological activities
TLDR
Results obtained indicate that Ro 11-2465 and CIT, as well as their desmethyl metabolites, are also potent 5-HT uptake inhibitors in vivo, however, only CIT and DCIT are concurrently devoid of effect on uptake of NA.
Pharmacology of cyanodothiepin (BTS 56 424), a selective 5‐hydroxytryptamine reuptake inhibitor
TLDR
Overall, cyanodothiepin is a potent and selective 5‐HT reuptake inhibitor which exhibits antidepressant potential and probably possesses a lower propensity to induce side effects associated with tricyclic antidepressants.
The thermogenic actions of α2‐adrenoceptor agonists in reserpinized mice are mediated via a central postsynaptic α2‐adrenoceptor mechanism
TLDR
The results suggest that α2‐adrenoceptor agonists reverse reserpine‐induced hypothermia via a central mechanism involving activation of postsynaptic α2-adrenOceptors in reserpinized mice.
Dual serotonin and noradrenaline uptake inhibitor class of antidepressants potential for greater efficacy or just hype?
  • D. Wong, F. Bymaster
  • Psychology, Biology
    Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques
  • 2002
TLDR
Comparative trials of dual uptake inhibitors against the other agents are needed to establish whether the dual uptake inhibitor show improvement in efficacy, rate of responders, antidepressive effects and/or remission.
Development of Antidepressant Drugs
TLDR
This article presents some of the background which attracted the attention, and some studies on the chemical series of phenoxyphenylpropylamines and the enantiomers of fluoxetine and its major metabolite norfluoxetines as inhibitors of 5-HT and NE uptake in vitro.
...
1
2
3
...

References

SHOWING 1-10 OF 12 REFERENCES
Importance of noradrenaline synthesis for the interaction between desipramine and reserpine
TLDR
An increase of the concentration of noradrenaline at the receptor sites might be expected as a consequence of the inhibitory action of desipramine on the catecholamine re-uptake at the nerve endings (Iversen, 1965).
Adrenergic mediation in the antagonism between desipramine and reserpine
TLDR
Preliminary experiments are reported designed to test if the effect of desipramine on reserpine-hypothermia could be interpreted as an interaction of desIPramine with the adrenergic system.
EFFECT OF IMIPRAMINE, AMITRIPTYLINE AND THEIR MONOMETHYL DERIVATIVES ON RESERPINE ACTIVITY
TLDR
The activity of desmethylimipramine may be differentiated on a pharmacological basis from that of the monoamine oxidase inhibitors and amphetamine because of the central effects of 5‐hydroxy‐ tryptophan and tryptamine and do not prevent the hypothermia induced by 5‐Hydroxytryptamine, α‐methyl‐dopa or chlorpromazine.
Tricyclic antidepressant agents. I. Comparison of the inhibition of the uptake of 3-H-noradrenaline and 14-C-5-hydroxytryptamine in slices and crude synaptosome preparations of the midbrain-hypothalamus region of the rat brain.
TLDR
The role of protein binding and diffusion barriers in the causation of the difference in the results obtained with the two preparations is discussed.
Interaction between imipramine‐like agents and catecholamine‐induced hyperthermia
TLDR
Desipramine increases the hyperthermic response induced by L‐dopa (in monoamine oxidase blocked rats), reserpine (immediately after intravenous injection) and dexamphetamine, while other types of hyperthermia, such as the one induced by phenethylamine in monoamines oxidase treated rats, and that by yeast, were not increased by desipramines.
3,4-Dihydroxyphenylalanine and 5-Hydroxytryptophan as Reserpine Antagonists
TLDR
It remains to be proved to what extent the central action of reserpine may be attributed to changes in brain catechol amines and/or 5-hydroxytryptamine.
Blochem . PharmacoJ . 27 : 193 - 198 Ther
  • 1978
...
1
2
...